Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Wilson Therapeutics in connection with the offer from Alexion
Mandate

Vinge advises Wilson Therapeutics in connection with the offer from Alexion

April 11, 2018

Alexion has announced a public cash offer to the shareholders of Wilson Therapeutics AB.


The offer values Wilson Therapeutics at approximately SEK 6,564 million. 
 
Vinge advises Wilson Therapeutics in connection with the offer. Vinge’s team is primarily composed of Erik Sjöman, Christian Lindhé, Astrid Karlsson and Philip Åberg. 

Related

Vinge advises Greenfood

 Vinge advises Greenfood in connection with the divestment of its Fresh Produce business to Dole.
October 21, 2026

Vinge has advised Investor in connection with acquisition of shares in EQT

 Vinge has advised Investor in connection with an acquisition of 12,500,000 shares in EQT AB from Wallenberg Investments for a total consideration of approximately SEK 3.5 billion.
October 19, 2026

Vinge has advised Oncopeptides in connection with a directed share issue

 Vinge has advised Oncopeptides in connection with a directed share issue, whereby Oncopeptides raises proceeds of SEK 100 million.
October 16, 2026